VEA
GMAB icon

Virtus ETF Advisers’s Genmab GMAB Stock Holding History

Virtus ETF Advisers’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,830
Closed -$827K – 531
2026
Q1 		$827K Buy
30,830
+3,335
+12% +$99.9K 0.38% 55
2025
Q4 		$847K Hold
27,495
– – 0.4% 56
2025
Q3 		$843K Hold
27,495
– – 0.46% 54
2025
Q2 		$568K Buy
+27,495
New +$564K 0.35% 81

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtus ETF Advisers's GMAB Position: Q2 2026 in Review

Virtus ETF Advisers sold out of Genmab (GMAB) in Q2 2026, closing a stake of 30,830 shares — an estimated $827K sold.

Virtus ETF Advisers first reported a position in GMAB in Q2 2025 and held it in 4 quarters. The position peaked at $847K in Q4 2025. 291 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Virtus ETF Advisers reported no remaining Genmab position as of Q2 2026 after selling out during the quarter.
  • Virtus ETF Advisers sold 30,830 Genmab shares in Q2 2026, an estimated $827K.
  • Virtus ETF Advisers first reported a position in Genmab in Q2 2025 and held it in 4 quarters.
  • Virtus ETF Advisers's Genmab position peaked at $847K in Q4 2025.
  • 291 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.